Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer

Table 2 Quality of life assessment (first-generation epidermal growth factor receptor-tyrosine kinase inhibitors vs chemotherapy)

Study	Treatment	Methoda
		FACT-L	Pb	TOI		LCS	P
IPASS[7]	Gefitinib	70.2%	< 0.0001	70.2%	< 0.0001	75.6%	0.000
	CBDCA + PTX	44.5%		38.3%		53.9%
OPTIMAL[13]	Erlotinib	74.3%	< 0.0001	73%	< 0.0001	77%	< 0.0001
	CBDCA + GEM	31.5%		25.9%		31.5%

^aEvaluable for quality of life population; logistic regression model with covariates;

^b6-point improvement (FACT-L and TOI); 2-point improvement (LCS), maintained ≥ 21 d. EGFR-TKIs: Epidermal growth factor receptor tyrosine kinase inhibitors; FACT-L: Functional assessment of cancer therapy–lung; TOI: Trial outcome index; LCS: Lung cancer subscale; CBDCA: Carboplatin; PTX: Paclitaxel; GEM: Gemcitabine.